Cargando…
Mechanisms of chemotherapy resistance in ovarian cancer
Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (...
Autores principales: | Ortiz, Mylena, Wabel, Emma, Mitchell, Kerry, Horibata, Sachi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255249/ https://www.ncbi.nlm.nih.gov/pubmed/35800369 http://dx.doi.org/10.20517/cdr.2021.147 |
Ejemplares similares
-
Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer
por: Maity, Jyotirindra, et al.
Publicado: (2022) -
Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022) -
Transcriptomic profile of intrinsically chemoresistant acute myeloid leukemia patients
por: Horibata, Sachi
Publicado: (2019) -
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
por: Pokhriyal, Ruchika, et al.
Publicado: (2019) -
Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies
por: Vasey, P A
Publicado: (2003)